The Medicines Company

(MDCO) Alert: Johnson Fistel Investigates Proposed Sale of The Medicines
Company; Is $85 a Fair Price?

SAN DIEGO- PRNewswire —November 25, 2019

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the
board members of The Medicines Company (NASDAQ: MDCO) breached their fiduciary duties
in connection with the proposed sale of the Company to Novartis AG.

On November 25, 2019, The Medicines Company announced that it had signed a definitive merger
agreement with Novartis AG. Under the terms of the deal, The Medicines Company stockholders
will receive $85 per share in cash.

The investigation concerns whether The Medicines Company board failed to satisfy its duties to
the Company shareholders, including whether the board adequately pursued alternatives to the
acquisition and whether the board obtained the best price possible for The Medicines Company
shares of common stock. Nationally recognized Johnson Fistel is investigating whether the
proposed deal represents adequate consideration, especially given that one Wall Street
analyst has a $100.00 price target on the stock.

If you are a shareholder of The Medicines Company and believe the proposed buyout price is too low or you’re interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in
California, New York, and Georgia. The firm represents individual and institutional investors in
shareholder derivative and securities class action lawsuits. For more information about the firm
and its attorneys, please visit https://www.johnsonfistel.com. Attorney advertising. Past results do
not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]
[Click here to join this action]

  • Plaintiff certifies that:
    • 1. Plaintiff did not acquire the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this private action or any other litigation under the federal or state securities laws.
    • 2. Plaintiff is willing to serve as a representative party, including providing testimony at deposition and trial, if necessary.
    • 3. Plaintiff represents and warrants that he/she/it is fully authorized to enter into and execute this certification.
    • 4. If a class action is filed, Plaintiff will not accept any payment for serving as a representative party on behalf of a class beyond the Plaintiff's pro rata share of any recovery, except such reasonable costs and expenses (including lost wages) directly relating to the representation of the class as ordered or approved by the court.
    • 5. For purposes of a class action, Plaintiff has made no transaction(s) during the Class Period in the debt or equity securities that are the subject of this action except those set forth below:
  • Acquisitions (include: date shares were acquired, number of shares acquired, and acquisition price per share. Separate each item with a comma. For multiple acquisitions, separate each acquisition with a new line):
  • Sales (include: date shares were sold, number of shares sold, and selling price per share. Separate each item with a comma. For multiple sales, separate each sale with a new line.):
  • During the three years prior to the date of this certification, Plaintiff has not sought to serve or be served as a representative party for a class in an action filed under the federal securities law except if detailed below:

Click to view Retention Agreement